Similarly, in murine models of triple-negative breast cancer, the dual PI3K/mTOR inhibitor gedatolisib has been shown to significantly enhance ICIs’ efficacy, resulting in robust tumor growth inhibition and the activation of anti-tumor immune responses [232]. This evidence concerns the gene MTOR and triple-negative breast carcinoma.